Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases - PubMed

Case Reports

Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases

C Díaz-Cascajo et al. Am J Dermatopathol. 1997 Dec.

Abstract

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcoma (FS)-like areas (DFSP-FS) is a peculiar neoplasm that combines microscopic findings of DFSP and FS. Because of the scarce number of cases published, tumor prognosis remains controversial. The clinical histories and the histologic material of 27 cases of DFSP were reviewed. Four of them showed fibrosarcomatous areas. Follow-up data, ranging from 12 to 125 months, were obtained in all four cases. Two patients had repeated local recurrences. One patient developed pulmonary metastases and died of disease 49 months after diagnosis. In the other two patients, no recurrences or metastases were detected at 12 and 70 months after local excision, respectively. Progressive increase of FS areas, cellular density, cellular atypia, and mitotic activity were observed during the recurrences. All cases showed diffuse positive immunostaining for CD34 in DFSP areas. Three cases were also CD34-positive in FS areas. Based on a careful review of the literature and our personal experience, we conclude that DFSP-FS is a rare variant of DFSP with a higher rate of local recurrences and more distant metastases than typical DFSP.

Similar articles

• Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.

  Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Mentzel T, et al. Am J Surg Pathol. 1998 May;22(5):576-87. doi: 10.1097/00000478-199805000-00009. Am J Surg Pathol. 1998. PMID: 9591728

• [Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].

  Zhang J, Wu N, Xia C, Wei X, Shi QL, Zhou XJ, Ma J. Zhang J, et al. Zhonghua Bing Li Xue Za Zhi. 2013 Nov;42(11):753-7. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 24447553 Chinese.

• CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans.

  Goldblum JR. Goldblum JR. Arch Pathol Lab Med. 1995 Mar;119(3):238-41. Arch Pathol Lab Med. 1995. PMID: 7534057

• A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.

  Liang CA, Jambusaria-Pahlajani A, Karia PS, Elenitsas R, Zhang PD, Schmults CD. Liang CA, et al. J Am Acad Dermatol. 2014 Oct;71(4):781-6. doi: 10.1016/j.jaad.2014.03.018. Epub 2014 Apr 19. J Am Acad Dermatol. 2014. PMID: 24755121 Review.

• Atrophic and plaquelike dermatofibrosarcoma protuberans.

  Davis DA, Sánchez RL. Davis DA, et al. Am J Dermatopathol. 1998 Oct;20(5):498-501. doi: 10.1097/00000372-199810000-00014. Am J Dermatopathol. 1998. PMID: 9790114 Review.

Cited by

• CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

  Eilers G, Czaplinski JT, Mayeda M, Bahri N, Tao D, Zhu M, Hornick JL, Lindeman NI, Sicinska E, Wagner AJ, Fletcher JA, Mariño-Enriquez A. Eilers G, et al. Mol Cancer Ther. 2015 Jun;14(6):1346-53. doi: 10.1158/1535-7163.MCT-14-0793. Epub 2015 Apr 7. Mol Cancer Ther. 2015. PMID: 25852058 Free PMC article.

• Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.

  Szollosi Z, Scholtz B, Egervari K, Nemes Z. Szollosi Z, et al. J Clin Pathol. 2007 Feb;60(2):190-4. doi: 10.1136/jcp.2006.037200. Epub 2006 May 26. J Clin Pathol. 2007. PMID: 16731589 Free PMC article.

• COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.

  Wang J, Morimitsu Y, Okamoto S, Hisaoka M, Ishida T, Sheng W, Hashimoto H. Wang J, et al. J Mol Diagn. 2000 Feb;2(1):47-52. doi: 10.1016/S1525-1578(10)60614-9. J Mol Diagn. 2000. PMID: 11272901 Free PMC article.

• Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

  Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Rutkowski P, et al. J Clin Oncol. 2010 Apr 1;28(10):1772-9. doi: 10.1200/JCO.2009.25.7899. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194851 Free PMC article.

• Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.

  Rutkowski P, Wozniak A, Switaj T. Rutkowski P, et al. Sarcoma. 2011;2011:959132. doi: 10.1155/2011/959132. Epub 2011 Mar 30. Sarcoma. 2011. PMID: 21559214 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Medical

  • MedlinePlus Health Information